{
 "name": "聖安生醫",
 "slug": "tw-6926",
 "aliases": [
  "聖安生醫股份有限公司",
  "Shine-On Bio",
  "6926"
 ],
 "ticker": "6926",
 "industry": "生技醫療業",
 "website": "https://www.shineon-bio.com",
 "summary": "聖安生醫（6926）是興櫃的生技醫療類股公司，2021 年成立，2022 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "聖安生醫股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "Shine-On Bio",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2022-11-25",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2021-04-06",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "黃秋錦",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "江宏哲",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 498000000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "安永聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.shineon-bio.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：SOA101",
   "value": "實體腫瘤｜第I／IIa期臨床獲准執行｜台灣、美國",
   "unit": "",
   "as_of": "2025-06-03",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=155148&spoke_date=20250603&co_id=6926&TYPEK=rotc",
   "note": "發言日期：114/06/03；主旨：本公司三特異性抗體抗癌新藥SOA101獲台灣衛生福利部食品 藥物管理署(TFDA)准予治療實體腫瘤(Solid Tumors) Phase I/IIa 人體臨床試驗執行。TFDA准予執行之公司通知，不是藥品上市許可；美國FDA許可依2024-12-24公告：https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&co_id=6926&spoke_date=20241224&spoke_time=151444&seq_no=1&TYPEK=rotc 。 試驗登錄：NCT07055594 https://clinicaltrials.gov/study/NCT07055594 。"
  },
  {
   "claim": "管線：SOB100",
   "value": "HLA-G標靶外泌體載體之健康受試者安全性｜第I期、登錄收案中｜美國",
   "unit": "",
   "as_of": "2026-01-26",
   "source": "https://clinicaltrials.gov/study/NCT07219940",
   "note": "NCT07219940；此登錄是健康受試者安全性試驗，不是癌症病人療效試驗；公司將其定位為未來腫瘤藥物載體。"
  },
  {
   "claim": "授權合作：外泌體小分子藥物裝載專利技術",
   "value": "Esco Aster Pte. Ltd.｜東南亞、澳洲及紐西蘭（不含台灣）｜2025-09-11",
   "unit": "",
   "as_of": "2025-09-11",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=175140&spoke_date=20250911&co_id=6926&TYPEK=rotc",
   "note": "發言日期：114/09/11；主旨：公告本公司與新加坡Esco Aster Pte. Ltd.簽署 外泌體裝載小分子藥物專利技術授權合約。授權範圍為裝載小分子藥物製程，不是SOB100標靶外泌體平台；契約期間另載2025-08-28至2045-08-27。"
  },
  {
   "claim": "簽約金：外泌體小分子藥物裝載專利技術",
   "value": 20000000,
   "unit": "新台幣",
   "as_of": "2025-09-11",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=175140&spoke_date=20250911&co_id=6926&TYPEK=rotc",
   "note": "發言日期：114/09/11；主旨：公告本公司與新加坡Esco Aster Pte. Ltd.簽署 外泌體裝載小分子藥物專利技術授權合約。交付專利相關文件後可收取，非已收款。"
  },
  {
   "claim": "里程碑金上限：外泌體小分子藥物裝載專利技術",
   "value": 180000000,
   "unit": "新台幣",
   "as_of": "2025-09-11",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=175140&spoke_date=20250911&co_id=6926&TYPEK=rotc",
   "note": "發言日期：114/09/11；主旨：公告本公司與新加坡Esco Aster Pte. Ltd.簽署 外泌體裝載小分子藥物專利技術授權合約。依技術開發期程收取。"
  },
  {
   "claim": "權利金比率：外泌體小分子藥物裝載專利技術",
   "value": 5,
   "unit": "%",
   "as_of": "2025-09-11",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=175140&spoke_date=20250911&co_id=6926&TYPEK=rotc",
   "note": "發言日期：114/09/11；主旨：公告本公司與新加坡Esco Aster Pte. Ltd.簽署 外泌體裝載小分子藥物專利技術授權合約。產品上市後按銷售淨額計算。"
  },
  {
   "claim": "授權合作：外泌體技術（順天承接）",
   "value": "順天醫藥生技股份有限公司（承接顥晟全部權利義務）｜全球（須行使選擇權）｜2026-05-14",
   "unit": "",
   "as_of": "2026-05-14",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=3&spoke_time=171524&spoke_date=20260514&co_id=6926&TYPEK=rotc",
   "note": "發言日期：115/05/14；主旨：公告本公司與顥晟生醫股份有限公司及順天醫藥生技股份有限公司 簽訂外泌體技術專屬授權契約之增補協議。原契約簽訂日2023-12-21；本日增補協議。完整全球專屬授權須依條件行使選擇權，不代表已行使。"
  },
  {
   "claim": "簽約金：外泌體技術（顥晟原約）",
   "value": 10000000,
   "unit": "新台幣",
   "as_of": "2023-12-21",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=183752&spoke_date=20231221&co_id=6926&TYPEK=rotc",
   "note": "發言日期：112/12/21；主旨：公告本公司與顥晟生醫股份有限公司簽訂專屬授權契約。交付專利與製程數據後可收取；是否已收另以2026-05-14公告為準。"
  },
  {
   "claim": "已收金額（公告日為準）：外泌體技術（顥晟原約簽約金）",
   "value": 10000000,
   "unit": "新台幣",
   "as_of": "2026-05-14",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=3&spoke_time=171524&spoke_date=20260514&co_id=6926&TYPEK=rotc",
   "note": "發言日期：115/05/14；主旨：公告本公司與顥晟生醫股份有限公司及順天醫藥生技股份有限公司 簽訂外泌體技術專屬授權契約之增補協議。含稅簽約金，僅此明確揭露收取金額；未推定後續款項已收。"
  },
  {
   "claim": "開發里程碑金：外泌體技術（順天承接第一階段）",
   "value": 6000000,
   "unit": "新台幣",
   "as_of": "2026-05-14",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=3&spoke_time=171524&spoke_date=20260514&co_id=6926&TYPEK=rotc",
   "note": "發言日期：115/05/14；主旨：公告本公司與顥晟生醫股份有限公司及順天醫藥生技股份有限公司 簽訂外泌體技術專屬授權契約之增補協議。含稅；增補協議後支付之早期開發款，未確認已收，不是全部里程碑金上限。"
  },
  {
   "claim": "開發里程碑金：外泌體技術（順天承接第二階段）",
   "value": 14000000,
   "unit": "新台幣",
   "as_of": "2026-05-14",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=3&spoke_time=171524&spoke_date=20260514&co_id=6926&TYPEK=rotc",
   "note": "發言日期：115/05/14；主旨：公告本公司與顥晟生醫股份有限公司及順天醫藥生技股份有限公司 簽訂外泌體技術專屬授權契約之增補協議。含稅；完成POC後決定行使選擇權才須支付，未確認已收。"
  },
  {
   "claim": "催化劑：SOB100",
   "value": "健康受試者第I期主要完成（試驗登錄預估）｜2026-12｜已公告",
   "unit": "",
   "as_of": "2026-01-26",
   "source": "https://clinicaltrials.gov/study/NCT07219940",
   "note": "NCT07219940；primaryCompletionDateStruct.type=ESTIMATED，不是主管機關目標日。"
  },
  {
   "claim": "催化劑：SOB100",
   "value": "健康受試者第I期試驗完成（試驗登錄預估）｜2027-03｜已公告",
   "unit": "",
   "as_of": "2026-01-26",
   "source": "https://clinicaltrials.gov/study/NCT07219940",
   "note": "NCT07219940；completionDateStruct.type=ESTIMATED。"
  },
  {
   "claim": "催化劑：SOA101",
   "value": "第I／II期主要完成（試驗登錄預估）｜2028-02｜已公告",
   "unit": "",
   "as_of": "2025-11-06",
   "source": "https://clinicaltrials.gov/study/NCT07055594",
   "note": "NCT07055594；primaryCompletionDateStruct.type=ESTIMATED；整體試驗完成預估2028-12在18個月窗口外，未列。"
  },
  {
   "claim": "授權合作：外泌體技術（顥晟原約；歷史交易）",
   "value": "顥晟生醫股份有限公司｜全球開發權（須行使選擇權）｜2023-12-21",
   "unit": "",
   "as_of": "2023-12-21",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=183752&spoke_date=20231221&co_id=6926&TYPEK=rotc",
   "note": "發言日期：112/12/21；主旨：公告本公司與顥晟生醫股份有限公司簽訂專屬授權契約。交付專利與製程數據後可收取；是否已收另以2026-05-14公告為準。 同源明載董事會通過並於當日完成簽約；原約先給專屬選擇權，交付專利及製程資料後可收1,000萬元。全球開發權須再決定行使選擇權；2026順天承接及後續開發款另列，不將兩個階段視為已完成全面授權。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6926.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}